Background: Antigen 85 complex of Mycobacterium tuberculosis includes three immunogenic proteins which are TB vaccine candidates of great importance. As they are very hard to be achieved in natural form, recombinant production of them fuels immunological experiments. Production of such apolar mycobacterial proteins located in the cell wall faces substantial challenges mainly regarding their solubility. This study reports the production of soluble recombinant Ag85B with an efficient yield. Materials and Methods: Ag85B gene was cloned in pJET1.2 and subsequently in pET32a (+). Both recombinant plasmids were sequenced. Expression of the recombinant protein was induced with 1mM IPTG. Recombinant Ag85B was purified through dissolving inclusions in 8M urea buffer, absorbing to Ni-NTA resins, washing by buffers with decreasing urea concentrations and finally eluted in imidazole. Western blot analysis was performed using anti-6His tag antibody, rabbit anti-M. tuberculosis polyclonal antibody and serum of hospitalized TB patients. Results: Ag85B gene was successfully cloned in both plasmid vectors. The recombinant Ag85B was expressed in E. coli host and purified with significant yield. Conclusion: Western blot results along with those of sequencing ensured accurate production of recombinant Ag85B and retaining of its antigenic structure.
INTRODUCTION
candidates for designing TB vaccines (3, 4) . This complex comprises three similar secreted proteins namely antigens 85A, 85B and 85C which have mycolyl transferase activity and play a major role in bacterial cell wall synthesis. This enzyme catalyzes the transfer of mycolic acids from a trehalose 6-monomycolate to another resulting in formation of trehalose 6-6' dimycolate also known as cord factor (5, 6) . This confirms that these enzymes play a critical role in physiology and pathogenesis of M.
tuberculosis (5, 7, 8) . On the other hand, use of recombinant antigens per se is suggested as an immunogenic factor and that is why production of recombinant protein antigens has been considered for use in immunization process (13, 14) .
Ag85B is one of the most abundant secreted proteins of M. tuberculosis which is secreted in the primary phase of illness and is frequently found in infected macrophages (15) . Considering the mentioned characteristics and since the immunogenicity of this protein has been confirmed, Ag85B is a promising candidate for immunization against TB. Similar to some other proteins present in the mycobacterial cell-wall, Ag85B shows apolar characteristics consistent with hydrophobic conditions (6, 16 
MATERIALS AND METHODS

Bacterial strains and plasmids
Mycobacterium tuberculosis
Cloning of Ag85B
Registered sequences of Ag85B gene of M. tuberculosis were obtained from NCBI database and evaluated using were screened with specific primers for antigen 85B using colony PCR. Enzyme digestion and sequencing (as explained earlier) was performed to ensure the accurate production of recombinant plasmids (pET32a-85B).
Expression and purification of recombinant protein
Ag85B (rAg85B)
Recombinant plasmid pET32a-85B was transferred into expression host E. coli Rosetta gami (DE3) pLysS.
Recombinant strains (RG-85B) were inoculated in 1 ml LB medium containing 50µg/ml ampicillin, 5µg/ml kanamycin, 34µg/ml chloramphenicol and 12.5µg/ml tetracycline and placed in the 37˚C incubator overnight.
This overnight culture was used for inoculation of 10 ml LB medium containing 50µg/ml ampicillin. Medium was placed in a rotary incubator shaker (250rpm) to an absorbance at 600 nm (A600) of 0.6. 
RESULTS
Cloning and Sequencing of Ag85B
Ag85B gene with 996 base pairs was amplified with 
Expression and purification of recombinant protein
Ag85B
Protein expression was observed on the SDS-PAGE gel in the range of 50kDa which is compatible with the molecular weight of our respective protein which was estimated to be 53kDa (Figure 1 ). Ag85B weighs about Recently, it has been confirmed that using protein booster for DNA vaccines or recombinant BCG can considerably stimulate the immune system and induce a more appropriate response. Additionally, some protein compounds alone or in combination with other proteins and various adjuvants have the ability to produce protective immune responses (14, (22) (23) (24) . In order to use TB bacilli proteins as the immunogenic factor or booster vaccine, recombinant production of them is necessary. 
